Given that insulin resistance is mainly identified by inactivation of insulin signaling receptors, treatments based on upregulation of serine/threonine protein kinase Akt/PKB may provide new pathways in the management of T2DM [25]. This evidence concerns the gene AKT1 and Insulin resistance.